

CENTER FOR DRUG EVALUATION AND RESEARCH

Approval Package for:

APPLICATION NUMBER:

207946Orig1s000

Trade Name: Invega Trinza

Generic Name: Paliperidone Palmitate

Sponsor: Janssen Pharmaceuticals, Inc.

Approval Date: May 18, 2015

Indications: Treatment of Schizophrenia in Patients After They Have Been Adequately Treated with Invega Sustenna (1-Month Paliperidone Palmitate Extended-Release Injectable Suspension) For at Least Four Months.

CENTER FOR DRUG EVALUATION AND RESEARCH

207946Orig1s000

CONTENTS

Reviews / Information Included in this NDA Review.

Approval Letter	X
Other Action Letters	
Labeling	X
REMS	
Summary Review	X
Officer/Employee List	X
Office Director Memo	
Cross Discipline Team Leader Review	X
Medical Review(s)	X
Chemistry Review(s)	X
Environmental Assessment	
Pharmacology Review(s)	X
Statistical Review(s)	X
Microbiology / Virology Review(s)	X
Clinical Pharmacology/Biopharmaceutics Review(s)	X
Other Reviews	X
Risk Assessment and Risk Mitigation Review(s)	
Proprietary Name Review(s)	X
Administrative/Correspondence Document(s)	X

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

207946Orig1s000

APPROVAL LETTER



NDA 207946

NDA APPROVAL

Janssen Pharmaceuticals, Inc.
Attention: Beth Geter-Douglass, Ph.D.
Associate Director, Global Regulatory Affairs
1125 Trenton-Harbourton Road
P.O. Box 200
Titusville, NJ 08560

Dear Dr. Geter-Douglass:

Please refer to your New Drug Application (NDA) dated and received November 18, 2014, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Invega Trinza (paliperidone palmitate) 273 mg, 410 mg, 546 mg, and 819 mg extended-release injectable suspension.

We acknowledge receipt of your amendments dated December 18, 2014, December 18, 2014, December 22, 2014, January 5, 2015, January 21, 2015, January 27, 2015, February 2, 2015, February 6, 2015, February 13, 2015, February 20, 2015, February 27, 2015, March 20, 2015, March 23, 2015, March 25, 2015, March 25, 2015, March 27, 2015, April 1, 2015, April 10, 2015, April 17, 2015, May 4, 2015, and May 12, 2015.

This new drug application provides for the use of Invega Trinza (paliperidone palmitate) extended-release injectable suspension for the treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

WAIVER OF PREGNANCY, LABOR AND DELIVERY, AND NURSING MOTHERS SUBSECTIONS

We are waiving the current requirements of 21 CFR 201.56(d)(1) and 201.57(c)(9)(i) through (iii), regarding the content and format of labeling for subsections 8.1 Pregnancy, 8.2 Labor and Delivery, and 8.3 Nursing Mothers of prescribing information. Your approved labeling for subsections 8.1, 8.2, and 8.3 reflects the content and format requirements of the Pregnancy and Lactation Labeling Rule (79 FR 72063, December 4, 2014) which implements on June 30, 2015.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide). Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND IMMEDIATE CONTAINER LABELS

We acknowledge your May 12, 2015 email containing final printed carton and container labels.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric studies requirement for this application because necessary studies are impossible or highly impracticable in patients aged birth to 12 years of age, and this product does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients **and** is not likely to be used in a substantial number of pediatric patients in patients aged 13-17 years.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please email Ann Sohn, Regulatory Project Manager, at ann.sohn@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, M.D.
CAPT USPHS
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosures:

Content of Labeling
Carton and Container Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
05/18/2015

(